➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Mallinckrodt
AstraZeneca
Johnson and Johnson
Baxter

Last Updated: May 13, 2021

DrugPatentWatch Database Preview

PROCARDIA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Procardia, and what generic alternatives are available?

Procardia is a drug marketed by Pfizer and is included in two NDAs.

The generic ingredient in PROCARDIA is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the nifedipine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Procardia

A generic version of PROCARDIA was approved as nifedipine by ACTAVIS ELIZABETH on September 20th, 1990.

  Get Started for $10

Drug patent expirations by year for PROCARDIA
Drug Prices for PROCARDIA

See drug prices for PROCARDIA

Recent Clinical Trials for PROCARDIA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Medical College of WisconsinN/A
Icahn School of Medicine at Mount SinaiPhase 4
High Risk Obstetrical ConsultantsEarly Phase 1

See all PROCARDIA clinical trials

Pharmacology for PROCARDIA
Paragraph IV (Patent) Challenges for PROCARDIA
Tradename Dosage Ingredient NDA Submissiondate
PROCARDIA CAPSULE;ORAL nifedipine 018482

US Patents and Regulatory Information for PROCARDIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer PROCARDIA nifedipine CAPSULE;ORAL 018482-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes   Get Started for $10   Get Started for $10   Get Started for $10
Pfizer PROCARDIA XL nifedipine TABLET, EXTENDED RELEASE;ORAL 019684-002 Sep 6, 1989 AB2 RX Yes No   Get Started for $10   Get Started for $10   Get Started for $10
Pfizer PROCARDIA nifedipine CAPSULE;ORAL 018482-002 Jul 24, 1986 DISCN Yes No   Get Started for $10   Get Started for $10   Get Started for $10
Pfizer PROCARDIA XL nifedipine TABLET, EXTENDED RELEASE;ORAL 019684-001 Sep 6, 1989 AB2 RX Yes No   Get Started for $10   Get Started for $10   Get Started for $10
Pfizer PROCARDIA XL nifedipine TABLET, EXTENDED RELEASE;ORAL 019684-003 Sep 6, 1989 AB2 RX Yes Yes   Get Started for $10   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PROCARDIA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer PROCARDIA nifedipine CAPSULE;ORAL 018482-002 Jul 24, 1986   Get Started for $10   Get Started for $10
Pfizer PROCARDIA nifedipine CAPSULE;ORAL 018482-001 Approved Prior to Jan 1, 1982   Get Started for $10   Get Started for $10
Pfizer PROCARDIA nifedipine CAPSULE;ORAL 018482-002 Jul 24, 1986   Get Started for $10   Get Started for $10
Pfizer PROCARDIA nifedipine CAPSULE;ORAL 018482-001 Approved Prior to Jan 1, 1982   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
AstraZeneca
Moodys
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.